Kymera Therapeutics, Inc. (KYMR) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
KYMR Revenue Analysis (2018–2025)
As of February 28, 2026, Kymera Therapeutics, Inc. (KYMR) generated trailing twelve-month (TTM) revenue of $39.2 million, reflecting significant decline in growth of -61.3% year-over-year. The most recent quarter (Q4 2025) recorded $2.9 million in revenue, up 3.5% sequentially.
Looking at the longer-term picture, KYMR's 5-year compound annual growth rate (CAGR) stands at +2.9%, indicating moderate growth over time. The company achieved its highest annual revenue of $78.6 million in 2023.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY), KYMR has underperformed the peer group in terms of revenue growth. Compare KYMR vs ARGX →
Peer Comparison
Compare KYMR's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KYMRCurrent | $39M | -61.3% | +2.9% | -891.3% | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% | |
| KNSA | $678M | +60.1% | - | 11.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $39.2M | -16.7% | $39.2M | 100.0% | $-349,400,000 | -891.3% |
| 2024 | $47.1M | -40.1% | $47.1M | 100.0% | $-261,635,000 | -555.8% |
| 2023 | $78.6M | +67.8% | $78.6M | 100.0% | $-165,530,000 | -210.6% |
| 2022 | $46.8M | -35.7% | $46.8M | 100.0% | $-161,256,000 | -344.4% |
| 2021 | $72.8M | +114.0% | $72.8M | 100.0% | $-100,530,000 | -138.0% |
| 2020 | $34.0M | +1060.0% | $34.0M | 100.0% | $-46,304,000 | -136.1% |
| 2019 | $2.9M | - | $2.1M | 71.9% | $-42,205,000 | -1438.5% |
| 2018 | $0 | - | $-205,000 | - | $-21,451,000 | - |
See KYMR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYMR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare KYMR vs AGIO
See how KYMR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is KYMR's revenue growth accelerating or slowing?
KYMR revenue declined -61.3% year-over-year, contrasting with the 5-year CAGR of +2.9%. TTM revenue fell to $39M. This reverses the prior growth trend.
What is KYMR's long-term revenue growth rate?
Kymera Therapeutics, Inc.'s 5-year revenue CAGR of +2.9% reflects the variable expansion pattern. Current YoY growth of -61.3% is below this long-term average.
How is KYMR's revenue distributed by segment?
KYMR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.